These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 22554121

  • 1. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS.
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [Abstract] [Full Text] [Related]

  • 2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, HEPNET. Greece Cohort Study Group.
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [Abstract] [Full Text] [Related]

  • 3. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ, Shim JH, Lee HC, Yoo DJ, Kim KM, Lim YS, Suh DJ.
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [Abstract] [Full Text] [Related]

  • 4. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG, Mohammed R, Yuen MF, Kao JH.
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [Abstract] [Full Text] [Related]

  • 5. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL.
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [Abstract] [Full Text] [Related]

  • 6. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR, Lee HJ, Kim TN, Lee KS.
    J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
    [Abstract] [Full Text] [Related]

  • 7. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM.
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H.
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
    [Abstract] [Full Text] [Related]

  • 9. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico P.
    Antivir Ther; 2005 Nov; 10(6):709-13. PubMed ID: 16218169
    [Abstract] [Full Text] [Related]

  • 10. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
    Huang G, Yang Y, Shen F, Pan ZY, Fu SY, Lau WY, Zhou WP, Wu MC.
    Ann Surg Oncol; 2013 May; 20(5):1482-90. PubMed ID: 23247982
    [Abstract] [Full Text] [Related]

  • 11. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P, Invernizzi F, Viganò M, Loglio A, Mangia G, Facchetti F, Primignani M, Jovani M, Iavarone M, Fraquelli M, Casazza G, de Franchis R, Colombo M.
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [Abstract] [Full Text] [Related]

  • 12. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL, Netherlands Association of Gastroenterologists and Hepatologists.
    Neth J Med; 2008 Nov; 66(7):292-306. PubMed ID: 18663260
    [Abstract] [Full Text] [Related]

  • 13. Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation.
    Fung J, Wong T, Chok K, Chan A, Sin SL, Cheung TT, Dai WC, Ng K, Ng K, Man K, Seto WK, Lai CL, Yuen MF, Lo CM.
    Transplantation; 2017 Oct; 101(10):2391-2398. PubMed ID: 28731907
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A.
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
    Lim SG, Aung MO, Mak B, Sutedja D, Lee YM, Lee GH, Fernandes M, Low HC, Lai V, Dan YY.
    J Clin Gastroenterol; 2011 Oct; 45(9):818-23. PubMed ID: 21921845
    [Abstract] [Full Text] [Related]

  • 16. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
    Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.
    Liver Int; 2010 Nov; 30(10):1461-70. PubMed ID: 20840396
    [Abstract] [Full Text] [Related]

  • 17. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection.
    Coppola N, Stanzione M, Messina V, Pisaturo M, De Pascalis S, Macera M, Tonziello G, Fiore M, Sagnelli C, Pasquale G, Sagnelli E.
    J Viral Hepat; 2012 Dec; 19(12):890-6. PubMed ID: 23121368
    [Abstract] [Full Text] [Related]

  • 18. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O.
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
    [Abstract] [Full Text] [Related]

  • 19. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
    Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM.
    J Viral Hepat; 2005 Jul; 12(4):386-92. PubMed ID: 15985009
    [Abstract] [Full Text] [Related]

  • 20. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
    Chung GE, Kim W, Lee JH, Kim YJ, Yoon JH, Lee JM, Lee JY, Kim SH, Kim D, Lee HS.
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.